Other languages EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
16.47 ^USD	-6.26%		-21.35%	-28.73%

Apr. 02	EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	CI
Mar. 18	EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	Apr. 02
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Mar. 07
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	Mar. 07
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	Mar. 04
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	Mar. 04
EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	Feb. 03
Eyepoint Pharmaceuticals Insider Sold Shares Worth $1,265,539, According to a Recent SEC Filing	Jan. 30
Eyepoint Pharmaceuticals Insider Sold Shares Worth $660,370, According to a Recent SEC Filing	Jan. 29
Eyepoint Pharmaceuticals Insider Sold Shares Worth $297,621, According to a Recent SEC Filing	Jan. 26
Eyepoint Pharmaceuticals Insider Sold Shares Worth $409,790, According to a Recent SEC Filing	Jan. 26
Eyepoint Pharmaceuticals Insider Sold Shares Worth $795,191, According to a Recent SEC Filing	Jan. 24
Eyepoint Pharmaceuticals Insider Sold Shares Worth $484,124, According to a Recent SEC Filing	Jan. 10
EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema	Jan. 10
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	Dec. 08
EyePoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	Dec. 08
Eyepoint Pharmaceuticals Insider Sold Shares Worth $990,000, According to a Recent SEC Filing	Dec. 06
Eyepoint Pharmaceuticals Insider Sold Shares Worth $415,200, According to a Recent SEC Filing	Dec. 06
EyePoint Pharmaceuticals Prices Offering of 11.8 Million Shares to Fund Macular Degeneration Study	Dec. 06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Other languages

Filters